TY - JOUR
T1 - Clinical evaluation of proton radiotherapy for non-small-cell lung cancer
AU - Shioyama, Yoshiyuki
AU - Tokuuye, Koichi
AU - Okumura, Toshiyuki
AU - Kagei, Kenji
AU - Sugahara, Shinji
AU - Ohara, Kiyoshi
AU - Akine, Yasuyuki
AU - Ishikawa, Shigemi
AU - Satoh, Hiroaki
AU - Sekizawa, Kiyohisa
N1 - Funding Information:
Supported by a Grant-in-Aid for Cancer Research (11-6) provided by the Ministry of Health, Labor and Welfare of the Japanese Government.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2003/5/1
Y1 - 2003/5/1
N2 - Purpose: To evaluate the clinical results of proton radiotherapy for patients with non-small-cell lung cancer (NSCLC). Methods and Materials: Between 1983 and 2000, 51 NSCLC patients were treated with proton beams at the University of Tsukuba. There were 28 patients in Stage I, 9 in Stage II, 8 in Stage III, 1 in Stage IV, and 5 with recurrent disease. Thirty-three patients had squamous cell carcinoma, 17 had adenocarcinoma, and 1 had large-cell carcinoma. Median fraction and total doses given were 3.0 Gy (range 2.0-6.0 Gy), and 76.0 Gy (range 49.0-93.0 Gy), respectively. Results: The 5-year overall survival rate was 29% for all patients, 70% for 9 Stage IA patients, and 16% for 19 Stage IB patients, respectively (IA vs. IB: p < 0.05). The 5-year in-field local control rate was higher in patients with Stage IA (89%) when compared with those with Stage IB (39%). Forty-seven patients (92%) experienced acute lung toxicity of Grade 1 or less; 3 had Grade 2, 1 had Grade 3, and none experienced Grade 4 or higher. Patients in the present series showed very little late toxicity. Conclusion: Proton therapy is a very safe and effective treatment for patients with NSCLC, especially for those with early stages. The relative merit of proton therapy in comparison with stereotactic photon radiotherapy or three-dimensional conformal photon radiotherapy remains to be defined through future clinical trials.
AB - Purpose: To evaluate the clinical results of proton radiotherapy for patients with non-small-cell lung cancer (NSCLC). Methods and Materials: Between 1983 and 2000, 51 NSCLC patients were treated with proton beams at the University of Tsukuba. There were 28 patients in Stage I, 9 in Stage II, 8 in Stage III, 1 in Stage IV, and 5 with recurrent disease. Thirty-three patients had squamous cell carcinoma, 17 had adenocarcinoma, and 1 had large-cell carcinoma. Median fraction and total doses given were 3.0 Gy (range 2.0-6.0 Gy), and 76.0 Gy (range 49.0-93.0 Gy), respectively. Results: The 5-year overall survival rate was 29% for all patients, 70% for 9 Stage IA patients, and 16% for 19 Stage IB patients, respectively (IA vs. IB: p < 0.05). The 5-year in-field local control rate was higher in patients with Stage IA (89%) when compared with those with Stage IB (39%). Forty-seven patients (92%) experienced acute lung toxicity of Grade 1 or less; 3 had Grade 2, 1 had Grade 3, and none experienced Grade 4 or higher. Patients in the present series showed very little late toxicity. Conclusion: Proton therapy is a very safe and effective treatment for patients with NSCLC, especially for those with early stages. The relative merit of proton therapy in comparison with stereotactic photon radiotherapy or three-dimensional conformal photon radiotherapy remains to be defined through future clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0037403118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037403118&partnerID=8YFLogxK
U2 - 10.1016/S0360-3016(02)04416-4
DO - 10.1016/S0360-3016(02)04416-4
M3 - Article
C2 - 12694818
AN - SCOPUS:0037403118
SN - 0360-3016
VL - 56
SP - 7
EP - 13
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 1
ER -
